Publicaciones en colaboración con investigadores/as de Hospital Virgen de la Arrixaca (22)

2023

  1. Circulating ST2, from biomarker to pathogenic mediator

    Revista Espanola de Cardiologia, Vol. 76, Núm. 9, pp. 672-674

2022

  1. Critical warm ischemia time point for cardiac donation after circulatory death

    American Journal of Transplantation, Vol. 22, Núm. 5, pp. 1321-1328

2019

  1. Galectina-3 as a biomarker of acute kidney injury risk in patients with decompensated heart failure

    Revista Clinica Espanola, Vol. 219, Núm. 6, pp. 315-319

  2. Temporal characterization of cardiac expression of glucose transporters SGLT and GLUT in an experimental model of myocardial infarction

    Diabetes and Metabolism

  3. Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction

    Journal of Molecular and Cellular Cardiology, Vol. 130, pp. 216-233

2018

  1. Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCα/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction

    Translational Research, Vol. 199, pp. 4-23

  2. Pulmonary Production of Soluble ST2 in Heart Failure

    Circulation. Heart failure, Vol. 11, Núm. 12, pp. e005488

  3. Short-term Serial Measurement of Galectin-3 in Hospitalized Patients With Acute Heart Failure

    Revista Espanola de Cardiologia, Vol. 71, Núm. 5, pp. 401-402

2017

  1. Concentración de relaxina en pacientes con insuficiencia cardiaca aguda. Respuesta

    Revista Espanola de Cardiologia

  2. Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes

    PLoS ONE, Vol. 12, Núm. 2

  3. Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction

    Journal of Cardiovascular Translational Research, Vol. 10, Núm. 5-6, pp. 460-469

2016

  1. Ausencia de implicación de la cistatina C en el remodelado ventricular y la insuficiencia cardiaca

    Revista Clinica Espanola, Vol. 216, Núm. 2, pp. 55-61

  2. Clinical relevance of sST2 in cardiac diseases

    Clinical Chemistry and Laboratory Medicine, Vol. 54, Núm. 1, pp. 29-35

  3. Concentración de relaxina en pacientes con insuficiencia cardiaca aguda: comportamiento y determinantes clínicos

    Revista Espanola de Cardiologia, Vol. 69, Núm. 12, pp. 1230-1232

  4. Early oxidative damage induced by doxorubicin: Source of production, protection by GKT137831 and effect on Ca2+ transporters in HL-1 cardiomyocytes

    Archives of Biochemistry and Biophysics, Vol. 594, pp. 26-36

  5. Reformulated meat products protect against ischemia-induced cardiac damage

    Food and Function, Vol. 7, Núm. 2, pp. 992-1001

2015

  1. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction

    JACC: Heart Failure, Vol. 3, Núm. 1, pp. 50-58

2014

  1. Ferritin heavy chain as main mediator of preventive effect of metformin against mitochondrial damage induced by doxorubicin in cardiomyocytes

    Free Radical Biology and Medicine, Vol. 67, pp. 19-29

  2. Galectin-3 expression in cardiac remodeling after myocardial infarction

    International Journal of Cardiology, Vol. 172, Núm. 1

  3. Modulation of IL-33/ST2 system in postinfarction heart failure: Correlation with cardiac remodelling markers

    European Journal of Clinical Investigation, Vol. 44, Núm. 7, pp. 643-651